Intellia Therapeutics
Stock Forecast, Prediction & Price Target
Intellia Therapeutics (NTLA) stock Price Target by analysts
$39
Potential upside: 280.48%
Intellia Therapeutics price prediction
What is Intellia Therapeutics stock analysts` prediction?
Intellia Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Intellia Therapeutics in the last 3 months, the avarage price target is $39, with a high forecast of $NaN. The average price target represents a 280.48% change from the last price of $10.25.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Intellia Therapeutics stock Price Target by analysts
Full breakdown of analysts given Intellia Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jay Olson Oppenheimer | 0% 0/1 | 11 months ago | $60 485.36% upside | $17.16 | StreetInsider | Previous targets (0) |
Jack Allen Robert W. Baird | 0% 0/2 | 11 months ago | $18 75.60% upside | $15.85 | StreetInsider | Previous targets (1) |
Luca Issi RBC Capital | 0% 0/2 | about 1 year ago | $54 426.82% upside | $22.38 | StreetInsider | Previous targets (1) |
Jack Allen Robert W. Baird | 0% 0/2 | over 1 year ago | $24 134.14% upside | $26 | StreetInsider | Previous targets (1) |
Dae Gon Ha Stifel Nicolaus | 0% 0/1 | over 1 year ago | $80 680.48% upside | $25.22 | StreetInsider | Previous targets (0) |
Kostas Biliouris BMO Capital | 50% 1/2 | over 1 year ago | $70 582.92% upside | $24.84 | StreetInsider | Previous targets (1) |
Unknown Cantor Fitzgerald | N/A | over 2 years ago | $67 553.65% upside | $42.44 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $120 1070.73% upside | $36.64 | Benzinga | N/A |
Unknown Credit Suisse | N/A | almost 3 years ago | $88 758.53% upside | $40.03 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $86 739.02% upside | $45.8 | Benzinga | N/A |
Unknown Chardan Capital | N/A | almost 3 years ago | $129 1158.53% upside | $53.3 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $152 1382.92% upside | $61.98 | Benzinga | N/A |
Unknown Chardan Capital | N/A | about 3 years ago | $146 1324.39% upside | $61.28 | Benzinga | N/A |
Kostas Biliouris BMO Capital | 50% 1/2 | over 3 years ago | $54 426.82% upside | $41.44 | TheFly | Previous targets (1) |
Steven Seedhouse Raymond James | 0% 0/2 | over 3 years ago | $105 924.39% upside | $47.57 | TipRanks Contributor | Previous targets (1) |
Luca Issi RBC Capital | 0% 0/2 | over 3 years ago | $150 1363.41% upside | $87.46 | TipRanks Contributor | Previous targets (1) |
Raju Prasad William Blair | 0% 0/1 | over 3 years ago | $144 1304.87% upside | $86.52 | TheFly | Previous targets (0) |
Joon Lee Truist Financial | 0% 0/1 | over 3 years ago | $160 1460.97% upside | $98.52 | StreetInsider | Previous targets (0) |
David Nierengarten Wedbush | 0% 0/1 | over 3 years ago | $108 953.65% upside | $94.53 | StreetInsider | Previous targets (0) |
Swapnil Malekar Piper Sandler | 0% 0/1 | over 3 years ago | $171 1568.29% upside | $94.53 | TheFly | Previous targets (0) |
Anthony Butler Roth Capital | 0% 0/1 | almost 4 years ago | $180 1656.09% upside | $137.51 | TheFly | Previous targets (0) |
Steven Seedhouse Raymond James | 0% 0/2 | about 4 years ago | $181 1665.85% upside | $167.31 | TipRanks | Previous targets (1) |
Salveen Richter Goldman Sachs | 0% 0/1 | about 4 years ago | $252 2358.53% upside | $167.31 | StreetInsider | Previous targets (0) |
Gena Wang Barclays | 0% 0/1 | about 4 years ago | $207 1919.51% upside | $165.16 | TipRanks | Previous targets (0) |
Maury Raycroft Jefferies | 100% 1/1 | over 4 years ago | $109 963.41% upside | $78.91 | TheFly | Previous targets (0) |
Intellia Therapeutics Financial Estimates
Intellia Therapeutics Revenue Estimates
Intellia Therapeutics EBITDA Estimates
Intellia Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $33.05M N/A | $52.12M 57.68% | $36.27M -30.40% | Avg: $59.76M Low: $6.12M High: $142.83M avg. 64.74% | Avg: $116.09M Low: $44.67M High: $254.11M avg. 94.25% | Avg: $644.14M Low: $247.90M High: $1.40B avg. 454.86% | Avg: $1.90B Low: $733.79M High: $4.17B avg. 195.99% |
Net Income
% change YoY
| $-259.71M N/A | $-490.20M -88.74% | $-481.19M 1.83% | Avg: $-530.14M Low: $-561.02M High: $-363.06M avg. -10.17% | Avg: $-556.96M Low: $-797.15M High: $-204.17M avg. -5.05% | Avg: $-146.66M Low: $-373.33M High: $-29.37M avg. 73.66% | Avg: $478.49M Low: $95.85M High: $1.21B avg. 426.25% |
EBITDA
% change YoY
| $-267.85M N/A | $-444.67M -66.01% | $-506.31M -13.86% | Avg: $-59.76M Low: $-142.83M High: $-6.12M avg. 88.19% | Avg: $-116.09M Low: $-254.11M High: $-44.67M avg. -94.25% | Avg: $-644.14M Low: $-1.40B High: $-247.90M avg. -454.86% | Avg: $-1.90B Low: $-4.17B High: $-733.79M avg. -195.99% |
EPS
% change YoY
| -$3.66 N/A | -$6.37 -74.04% | -$5.42 14.91% | Avg: -$5.33 Low: -$6.32 High: -$4.09 avg. 1.70% | Avg: -$5.42 Low: -$8.98 High: -$2.3 avg. -1.67% | Avg: -$1.65 Low: -$4.21 High: -$0.33 avg. 69.50% | Avg: $5.39 Low: $1.08 High: $13.72 avg. 426.25% |
Operating Expenses
% change YoY
| $300.90M N/A | $510.28M 69.58% | $551.56M 8.08% | Avg: $105.28M Low: $10.78M High: $251.65M avg. -80.91% | Avg: $204.53M Low: $78.71M High: $447.70M avg. 94.25% | Avg: $1.13B Low: $436.77M High: $2.48B avg. 454.86% | Avg: $3.35B Low: $1.29B High: $7.35B avg. 195.99% |
FAQ
What is Intellia Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 121.17% in 2025-2028.
We have gathered data from 20 analysts. Their low estimate is -561.02M, average is -530.14M and high is -363.06M.
What is Intellia Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 202.46% in 2025-2028.
We have gathered data from 21 analysts. Their low revenue estimate is $6.12M, average is $59.76M and high is $142.83M.
What is Intellia Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 123.94% in 2025-2028.
We have gathered data from 20 analysts. Their low earnings per share estimate is -$6.32, average is -$5.33 and high is $-4.09.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Intellia Therapeutics stock. The most successful analyst is Jay Olson.